Biotech
Regional Biotech Hubs Gain Momentum as States and Federal Programs Expand
As pharmaceutical manufacturing investment reaches historic levels, state and federal programs are pouring resources into regional biotech hubs. Pennsylvania and New York launched new initiatives this year, while Kansas City and Central Virginia secured federal funding. Industry experts note that incentives alone rarely dictate site decisions, but they help build ecosystems that attract major projects, as seen in Richmond and Huntsville.
Taiho and Cullinan Data Intensify Competition in Lung Cancer Drug Market
Taiho Oncology and Cullinan Therapeutics announced that their targeted therapy zipalertinib, combined with chemotherapy, met the primary endpoint in a Phase 3 trial for first-line lung cancer with EGFR exon 20 insertions. The study was halted early due to clear efficacy. This development adds pressure to an already competitive market, with FDA review for second-line use pending by Feb. 27.
Definium Therapeutics Reports Positive Phase 3 Results for LSD-Based Pill in Generalized Anxiety Disorder
Definium Therapeutics announced positive topline results from its Phase 3 VOYAGE study of DT120, an orally disintegrating tablet containing pharmaceutical-grade LSD, in generalized anxiety disorder. The drug met all key secondary endpoints, with a mean 11.6-point reduction on a 56-point anxiety scale at 12 weeks post-dose, exceeding the placebo arm by 5.4 points and surpassing Wall Street's anticipated five-point separation. No new safety concerns emerged. Shares rose 15% at market open before settling around $43. A second Phase 3 trial in GAD is expected to report data in September, with additional readouts in major depressive disorder and PTSD planned for next year.
Silence Therapeutics Leverages 'Differentiated' Data to Raise $175M; UK Regulator Reaffirms Childhood Vaccine Safety
Silence Therapeutics' experimental RNAi therapy divesiran met its Phase 2 endpoint in polycythemia vera, driving shares up ~30% and enabling a $175M capital raise. The UK's MHRA reaffirmed vaccine safety following US policy shifts. In other news, FDA issued a complete response letter to ITM for its Lutathera competitor, AbCellera reported strong Phase 2 data for its menopause drug ABCL635, and BioMarin discontinued BMN 401 after a Phase 3 miss.
Boulevard Bio launches with $65M to develop next-generation autoimmune therapies
Boulevard Bio, a new startup co-founded by pioneering autoimmune disease researcher Georg Schett, launched Wednesday with $65 million in funding and three experimental drugs. The lead candidate, BLVD-101, is a bispecific antibody for IgA nephropathy currently in early testing, while BLVD-201, a trispecific medicine licensed from China's METiS TechBio, targets B cells in autoimmune conditions. The company aims to offer more practical alternatives to complex cell therapies.